These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15567447)

  • 1. A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays.
    Carlsson SC; Mattsson C; Eriksson UG; Sarich TC; Wåhlander K; Eliasson A; Karlson BW; Sheth SB; Held P
    Thromb Res; 2005; 115(1-2):9-18. PubMed ID: 15567447
    [No Abstract]   [Full Text] [Related]  

  • 2. A step change in oral anticoagulation: lack of coagulation monitoring with ximelagatran.
    Carlsson SC; Schulman S
    Semin Vasc Med; 2005 Aug; 5(3):259-65. PubMed ID: 16123913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction.
    Christersson C; Oldgren J; Bylock A; Wallentin L; Siegbahn A
    J Thromb Haemost; 2005 Oct; 3(10):2245-53. PubMed ID: 16194202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of ximelagatran in an historical perspective.
    Gustafsson D
    Semin Vasc Med; 2005 Aug; 5(3):227-34. PubMed ID: 16123909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of action of the oral direct thrombin inhibitor ximelagatran.
    Mattsson C; Sarich TC; Carlsson SC
    Semin Vasc Med; 2005 Aug; 5(3):235-44. PubMed ID: 16123910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulant action of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in umbilical cord and adult plasma: an in vitro examination.
    Koestenberger M; Gallistl S; Cvirn G; Baier K; Leschnik B; Muntean W
    Thromb Res; 2005; 115(1-2):135-42. PubMed ID: 15567465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation.
    Halperin JL
    J Am Coll Cardiol; 2005 Jan; 45(1):1-9. PubMed ID: 15629364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ximelagatran: pharmacokinetics and pharmacodynamics of a new strategy for oral direct thrombin inhibition.
    Kereiakes DJ
    Rev Cardiovasc Med; 2004; 5 Suppl 5():S4-11. PubMed ID: 15619615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT.
    Cimenti C; Koestenberger M; Leschnik B; Haidl H; Muntean W
    Thromb Res; 2007; 119(3):361-7. PubMed ID: 16712904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combination of a thrombin inhibitor and dexamethasone prevents the development of experimental disseminated intravascular coagulation in rats.
    Elg M; Gustafsson D
    Thromb Res; 2006; 117(4):429-37. PubMed ID: 15869787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low potential for interactions between melagatran/ximelagatran and other drugs, food, or alcohol.
    Wolzt M; Sarich TS; Eriksson UG
    Semin Vasc Med; 2005 Aug; 5(3):254-8. PubMed ID: 16123912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The oral direct thrombin inhibitor, ximelagatran, an alternative for anticoagulant treatment during the puerperium and lactation.
    Hellgren M; Johansson S; Eriksson UG; Wåhlander K
    BJOG; 2005 May; 112(5):579-83. PubMed ID: 15842280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel oral anticoagulants and diet: the potential for interaction.
    Kamali F
    Am J Hematol; 2009 Apr; 84(4):260-1. PubMed ID: 19253346
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial.
    Tangelder MJ; Frison L; Weaver D; Wilcox RG; Bylock A; Emanuelsson H; Held P; Oldgren J
    Am Heart J; 2008 Feb; 155(2):382-7. PubMed ID: 18215612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran.
    Harenberg J; Jörg I; Weiss C
    Int J Toxicol; 2006; 25(3):165-9. PubMed ID: 16717032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models.
    Furugohri T; Shiozaki Y; Muramatsu S; Honda Y; Matsumoto C; Isobe K; Sugiyama N
    Eur J Pharmacol; 2005 May; 514(1):35-42. PubMed ID: 15878322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era..
    Mohapatra R; Tran M; Gore JM; Spencer FA
    Am Heart J; 2005 Jul; 150(1):19-26. PubMed ID: 16084146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of ximelagatran.
    Wolzt M; Sarich TS; Eriksson UG
    Semin Vasc Med; 2005 Aug; 5(3):245-53. PubMed ID: 16123911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion.
    Eriksson UG; Dorani H; Karlsson J; Fritsch H; Hoffmann KJ; Olsson L; Sarich TC; Wall U; Schützer KM
    Drug Metab Dispos; 2006 May; 34(5):775-82. PubMed ID: 16455803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.
    Albers GW;
    Am J Manag Care; 2004 Dec; 10(14 Suppl):S462-9; discussion S469-73. PubMed ID: 15696910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.